BC Innovations | Apr 15, 2019
Distillery Therapeutics

Inhibiting NOX2 or FOXC1 to treat AML and CML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML) Cell culture and mouse studies suggest inhibiting NOX2 or its downstream mediator FOXC1 could help treat AML and CML. In AML cells from...
BC Innovations | Sep 29, 2016
Distillery Therapeutics

Therapeutics: NADPH oxidase 2 (NOX2)

Infectious disease INDICATION: Influenza virus; Staphylococcus Mouse studies suggest inhibiting NOX2 could help treat post-influenza pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). In mice co-infected with influenza virus and MRSA and receiving antibiotic therapy, knockout...
BC Innovations | Jul 17, 2014
Strategy

Partnering in pediatrics

Alexion Pharmaceuticals Inc. is hoping that its research collaboration with Cincinnati Children's Hospital Medical Center will help the biotech build out a rare disease pipeline that currently is dominated by a single molecule- Soliris eculizumab....
BC Innovations | Nov 8, 2012
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models NADPH oxidase 2 (Nox2)-deficient, lupus-prone mice Nox2-deficient, lupus-prone mice could be useful models for severe systemic lupus erythematosus (SLE). The mice were generated by crossing...
BC Innovations | Mar 8, 2012
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Neutrophil cytosolic factor 2 (NCF2; p67phox); NADPH oxidase 2 (NOX2); Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1; RAC1)...
BC Innovations | Mar 8, 2012
Distillery Therapeutics

Indication: Autoimmune Disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Indoleamine 2, 3-dioxygenase (INDO; IDO) Mouse studies suggest IDO could help treat and prevent autoimmune diseases. In lupus-prone mice, an IDO inhibitor...
BC Innovations | Jan 6, 2011
Strategy

LU Bio: Swedish hybrid

Lund University Bioscience AB is not a typical investment company or VC. As a kind of hybrid between a company, an incubator and a VC, LU Bio seeks out technology with commercial potential from academic...
BC Innovations | Sep 2, 2010
Targets & Mechanisms

Ketamine meets mTOR

A team from Yale School of Medicine has found an mTOR-mediated mechanism that could help explain how the anesthetic ketamine is able to reduce depression more rapidly than standard antidepressants. 1 The researchers now hope...
BC Innovations | Sep 2, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology NADPH oxidase 2 (NOX2) Mouse studies suggest that inhibiting NOX2 in the prefrontal cortex could help treat psychosis associated with schizophrenia. In a mouse...
BC Innovations | Aug 12, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neuropathy; pain; nerve damage NADPH oxidase 2 (NOX2) Mouse studies suggest that NOX2 inhibitors or antioxidants could help treat neuropathic pain after peripheral nerve injury....
Items per page:
1 - 10 of 11